<p>Beam Therapeutics Inc. announced the completion of an asset transaction in which its 75 million shares of Orbital Therapeutics, representing about 17% ownership, were converted into $255.1 million in cash following Orbital’s acquisition by Bristol-Myers Squibb. Beam may receive up to an additional $26.3 million pending certain escrow releases. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-316043), on December 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

BEAM

<p>Beam Therapeutics Inc. has completed an asset transaction, converting its 75 million shares in Orbital Therapeutics into $255.1 million in cash after Orbital's acquisition by Bristol-Myers Squibb. Beam may also receive an additional $26.3 million pending certain escrow releases. This information was originally published by Beam Therapeutics via the EDGAR system.</p>

Beam Therapeutics Nets $255 Million From Orbital Therapeutics Sale